SBT777101

Phase 1Biologic

SSonoma Biotherapeutics, Inc.

SBT777101 is one of 86 biologic programs targeting Rheumatoid Arthritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Hidradenitis SuppurativaActive, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Hidradenitis SuppurativaPhase 1

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Preclinical

47 2

Actemra

Simponi

19 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

Arcoxia

Novartis

Preclinical

4 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Actos

Takeda

Preclinical

2 9

Celexa

AbbVie

Preclinical

1 10

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Hidradenitis Suppurativa

NCT06361836

Phase 1Recruiting

Rheumatoid Arthritis

NCT06201416

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa1 trial

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

Active, not recruiting·SSonoma Biotherapeutics, Inc.·Phase 1·NCT06361836·24 enrolled

Rheumatoid Arthritis1 trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects With Rheumatoid Arthritis

Recruiting·SSonoma Biotherapeutics, Inc.·Phase 1·NCT06201416·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SBT777101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SBT777101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SBT777101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sonoma Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSonoma Biotherapeutics, Inc.

SBT777101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hidradenitis Suppurativa1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News